Next Article in Journal
In Vitro Fermentation of Sheep and Cow Milk Using Infant Fecal Bacteria
Previous Article in Journal
The Role of Vitamin D in Respiratory Allergies Prevention. Why the Effect Is so Difficult to Disentangle?
Article

Novel Therapeutic Approach for the Management of Mood Disorders: In Vivo and In Vitro Effect of a Combination of L-Theanine, Melissa officinalis L. and Magnolia officinalis Rehder & E.H. Wilson

1
Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology, University of Florence, Viale G. Pieraccini 6, 50139 Florence, Italy
2
Department of Biotechnology, Chemistry and Pharmacy-Department of Excellence 2018-2022, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
3
Department of Physical Sciences, Earth and Environment, University of Siena, Strada Laterina 8, 53100 Siena, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Nutrients 2020, 12(6), 1803; https://doi.org/10.3390/nu12061803
Received: 14 April 2020 / Revised: 19 May 2020 / Accepted: 16 June 2020 / Published: 17 June 2020
Mood disorders represent one of the most prevalent and costly psychiatric diseases worldwide. The current therapies are generally characterized by several well-known side effects which limit their prolonged use. The use of herbal medicine for the management of several psychiatric conditions is becoming more established, as it is considered a safer support to conventional pharmacotherapy. The aim of this study was to investigate the possible anxiolytic and antidepressant activity of a fixed combination of L-theanine, Magnolia officinalis, and Melissa officinalis (TMM) in an attempt to evaluate how the multiple modulations of different physiological systems may contribute to reducing mood disorders. TMM showed an anxiolytic-like and antidepressant-like activity in vivo, which was related to a neuroprotective effect in an in vitro model of excitotoxicity. The effect of TMM was not altered by the presence of flumazenil, thus suggesting a non-benzodiazepine-like mechanism of action. On the contrary, a significant reduction in the effect was observed in animals and neuronal cells co-treated with AM251, a cannabinoid receptor type 1 (CB1) antagonist, suggesting that the endocannabinoid system may be involved in the TMM mechanism of action. In conclusion, TMM may represent a useful and safe candidate for the management of mood disorders with an innovative mechanism of action, particularly as an adjuvant to conventional therapies. View Full-Text
Keywords: mood disorders; L-theanine; excitotoxicity; neuroprotection; endocannabinoid system; CB1; flumazenil; anxiety mood disorders; L-theanine; excitotoxicity; neuroprotection; endocannabinoid system; CB1; flumazenil; anxiety
Show Figures

Graphical abstract

MDPI and ACS Style

Borgonetti, V.; Governa, P.; Biagi, M.; Galeotti, N. Novel Therapeutic Approach for the Management of Mood Disorders: In Vivo and In Vitro Effect of a Combination of L-Theanine, Melissa officinalis L. and Magnolia officinalis Rehder & E.H. Wilson. Nutrients 2020, 12, 1803. https://doi.org/10.3390/nu12061803

AMA Style

Borgonetti V, Governa P, Biagi M, Galeotti N. Novel Therapeutic Approach for the Management of Mood Disorders: In Vivo and In Vitro Effect of a Combination of L-Theanine, Melissa officinalis L. and Magnolia officinalis Rehder & E.H. Wilson. Nutrients. 2020; 12(6):1803. https://doi.org/10.3390/nu12061803

Chicago/Turabian Style

Borgonetti, Vittoria, Paolo Governa, Marco Biagi, and Nicoletta Galeotti. 2020. "Novel Therapeutic Approach for the Management of Mood Disorders: In Vivo and In Vitro Effect of a Combination of L-Theanine, Melissa officinalis L. and Magnolia officinalis Rehder & E.H. Wilson" Nutrients 12, no. 6: 1803. https://doi.org/10.3390/nu12061803

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop